Lacklustre Performance Is Driving Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Low P/S

Simply Wall St.

Feb 03

You may think that with a price-to-sales (or "P/S") ratio of 5.8x Shandong Boan Biotechnology Co., Ltd. (HKG:6955) is definitely a stock worth checking out, seeing as almost half of all the Biotechs ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608810642"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608810642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608810642?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-03 07:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608810642","market":"sg","top_or_hot":-1,"title":"Lacklustre Performance Is Driving Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Low P/S","media":"Simply Wall St.","content":"<div>\n<p>You may think that with a price-to-sales (or \"P/S\") ratio of 5.8x Shandong Boan Biotechnology Co., Ltd. (HKG:6955) is definitely a stock worth checking out, seeing as almost half of all the Biotechs ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6955/shandong-boan-biotechnology-shares/news/lacklustre-performance-is-driving-shandong-boan-biotechnolog\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lacklustre Performance Is Driving Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Low P/S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLacklustre Performance Is Driving Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Low P/S\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6955/shandong-boan-biotechnology-shares/news/lacklustre-performance-is-driving-shandong-boan-biotechnolog><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may think that with a price-to-sales (or \"P/S\") ratio of 5.8x Shandong Boan Biotechnology Co., Ltd. (HKG:6955) is definitely a stock worth checking out, seeing as almost half of all the Biotechs ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6955/shandong-boan-biotechnology-shares/news/lacklustre-performance-is-driving-shandong-boan-biotechnolog\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6955/shandong-boan-biotechnology-shares/news/lacklustre-performance-is-driving-shandong-boan-biotechnolog","article_id":"2608810642","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6955/shandong-boan-biotechnology-shares/news/lacklustre-performance-is-driving-shandong-boan-biotechnolog","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608810642","pubTimestamp":1770075523,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"You may think that with a price-to-sales (or \"P/S\") ratio of 5.8x Shandong Boan Biotechnology Co., Ltd. ( HKG:6955 ) is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"91348":"深圳市道通科技股份有限公司（临时代码）","BK1161":"生物科技","06955":"博安生物"},"translate_title":"业绩低迷导致山东博安生物科技有限公司（HKG：6955）市盈率较低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91348":1.5,"06955":1.5},"content_text":"You may think that with a price-to-sales (or \"P/S\") ratio of 5.8x Shandong Boan Biotechnology Co., Ltd. (HKG:6955) is definitely a stock worth checking out, seeing as almost half of all the Biotechs companies in Hong Kong have P/S ratios greater than 13.6x and even P/S above 83x aren't out of the ordinary.   However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.    This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.  See our latest analysis for Shandong Boan Biotechnology SEHK:6955 Price to Sales Ratio vs Industry February 2nd 2026Advertisement What Does Shandong Boan Biotechnology's Recent Performance Look Like?  Shandong Boan Biotechnology could be doing better as it's been growing revenue less than most other companies lately.   It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio.  If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.      Keen to find out how analysts think Shandong Boan Biotechnology's future stacks up against the industry? In that case, our free report is a great place to start.  Is There Any Revenue Growth Forecasted For Shandong Boan Biotechnology?   There's an inherent assumption that a company should far underperform the industry for P/S ratios like Shandong Boan Biotechnology's to be considered reasonable.   Taking a look back first, we see that the company managed to grow revenues by a handy 5.1% last year.   This was backed up an excellent period prior to see revenue up by 106% in total over the last three years.  Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.     Turning to the outlook, the next year should generate growth of 44%  as estimated by the only analyst watching the company.  With the industry predicted to deliver 610% growth, the company is positioned for a weaker revenue result.  With this information, we can see why Shandong Boan Biotechnology is trading at a P/S lower than the industry.  Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.    The Bottom Line On Shandong Boan Biotechnology's P/S  We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.  We've established that Shandong Boan Biotechnology maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected.  Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S.  Unless these conditions improve, they will continue to form a barrier for the share price around these levels.      Before you take the next step, you should know about the 2 warning signs for Shandong Boan Biotechnology that we have uncovered.   If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings). New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}